Last reviewed · How we verify
NCT04794465
Asymptomatic Inflammatory Bowel Disease in Catalonia
trial testing Colorectal cancer screening in Inflammatory Bowel Diseases in 200 participants. Status unknown.
15 July 2021
Quick facts
| Lead sponsor | Corporacion Parc Tauli |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 April 2021 |
| Primary completion | 15 July 2021 |
| Estimated completion | 31 October 2021 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Colorectal cancer screening
Conditions studied
- Inflammatory Bowel Diseases — all drugs for Inflammatory Bowel Diseases →
Sponsor
Corporacion Parc Tauli — full company profile →
Who can join
18 and older, any sex, with Inflammatory Bowel Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An early treatment of inflammatory bowel disease (IBD) has been proposed to correlate to better outcomes. In Catalonia the screening programme was implemented in all the territory in 2015. The aim of this study is to describe the natural history of the asymptomatic IBD detected during colorectal cancer population screening.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04794465
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Inflammatory Bowel Diseases
Currently open trials in the same condition.
- NCT07520747 — A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea · recruiting
- NCT07349472 — Pentoxifylline in Patients With Ulcerative Colitis · Phase 2 · recruiting
- NCT07033208 — Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance · NA · recruiting
- NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
- NCT06453317 — Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis · Phase 2 · recruiting
Other Corporacion Parc Tauli trials
Trials by the same sponsor.
- NCT07331805 — Conservative Management in Primary Spontaneous Pneumothorax: a Multicenter Randomized Non-inferiority Study · NA · not yet recruiting
- NCT06873360 — Medical Device for Oxaliplatin-Induced Neuropathy in Gastrointestinal Cancer Patients · completed
- NCT06900335 — Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact · completed
- NCT06511700 — Implementation of the Intravitreal Injection Administered by Nurses · enrolling by invitation
- NCT07298720 — Assessing Fluid-responsiveness Using Non-invasive Hybrid Diffuse Optics on Peripheral Muscle · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04794465 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Corporacion Parc Tauli
- Last refreshed: 12 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04794465.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing